Latest News and Press Releases

First Quarter and Recent Company Highlights: Global revenue up 34% versus Q1 2018Regulatory approval obtained for ILUVIEN® in 17 EU countries for the treatment of Non-Infectious Posterior...

GAAP Net Loss cut by 34% from $33.2 in 2016 to $22.0 million in 2017Adjusted EBITDA loss reduced by 61% from $22.8 million in 2016 to $8.8 million 2017Filed for Type II variation for uveitis in Europe...

ATLANTA, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today...

ATLANTA, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Alimera Sciences (NASDAQ:ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will...

ATLANTA, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...

ATLANTA, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today...

ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today...

ATLANTA, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today...

ATLANTA, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today...

Net Revenue of $9.8 million for the third quarter of 2017 compared to $8.3 million for the third quarter of 2016, an 18% increaseGAAP Net Loss of $5.3 million for the third quarter of 2017 compared to...